Yttrium‑90 Radioembolization Induced Liver Injury

Overview

Yttrium‑90 (Y‑90) radioembolization is a minimally invasive, image‑guided therapy that delivers tiny glass or resin microspheres loaded with the beta‑emitting radioisotope Y‑90 directly into the hepatic artery. The radiation destroys tumor cells while sparing most of the surrounding healthy liver tissue. It is most commonly used for primary liver cancer (hepatocellular carcinoma, HCC) and metastatic disease from colorectal cancer, neuroendocrine tumors, or breast cancer.

Although the procedure is generally safe, up to 5‑15 % of patients develop a clinically significant liver injury within weeks to months after treatment. This injury, sometimes called **Y‑90‑related liver disease** or **radiation‑induced liver disease (RILD)**, can range from mild transaminase elevation to severe hepatic failure.

Who it affects: Adults with liver‑directed cancer who undergo Y‑90 radioembolization. The risk is higher in patients who already have compromised liver function (Child‑Pugh B/C), large tumor burden, prior external‑beam radiation, or concurrent systemic chemotherapy.

Prevalence (based on large series and registries):

• Overall incidence of any liver injury: 8‑12 %.
• Severe injury (grade ≥ 3 per CTCAE): 2‑5 %.
• Mortality directly attributable to radiation‑induced liver failure: <1 % in contemporary series (improved with better patient selection) 【ref1】.

Symptoms

The presentation can be acute (days) or delayed (weeks‑months). Symptoms often mimic other liver disorders; clinicians must keep a high index of suspicion.

Common symptoms

• Right upper quadrant (RUQ) discomfort or pain – dull ache or sharp pain, often worsened by deep breaths.
• Abdominal fullness or bloating – due to ascites or hepatic congestion.
• Jaundice – yellowing of skin and eyes indicating bilirubin rise.
• Fatigue or malaise – common in any liver disease.
• Nausea & loss of appetite – may lead to weight loss.
• Pruritus (itching) – result of cholestasis.
• Fever – may indicate infection or inflammatory response.

Less frequent but important signs

• Elevated liver enzymes (AST, ALT) detected on routine labs.
• Enlarged liver on physical exam (hepatomegaly).
• Ascites: fluid accumulation detectable by shifting dullness or ultrasound.
• Encephalopathy: confusion, altered mental status (sign of hepatic decompensation).
• Hematemesis or melena – from portal hypertension‑related varices.

Causes and Risk Factors

Mechanism of injury

Y‑90 microspheres emit high‑energy beta particles that travel < 2.5 mm in tissue, delivering a focused dose of radiation (typically 80‑150 Gy). When the dose exceeds the liver’s tolerance, several pathophysiologic processes occur:

• Sinusoidal endothelial damage → congestion and necrosis.
• Hepatocyte apoptosis → transaminase rise.
• Fibrogenic cytokine release → early fibrosis.
• Portal venous hypertension → ascites, varices.

Major risk factors

• Pre‑existing liver dysfunction – Child‑Pugh B/C, high MELD score.
• Large tumor burden – >50 % of liver volume involved.
• Prior liver irradiation – cumulative dose increases toxicity.
• Concurrent systemic therapy – especially oxaliplatin or bevacizumab, which can sensitize liver to radiation.
• High liver absorbed dose – >120 Gy (dose‑volume parameters from MAA SPECT/CT planning).
• Portal vein thrombosis – reduces liver’s ability to clear radiation‑induced debris.
• Age >75 years and comorbidities (diabetes, obesity).

Diagnosis

Diagnosis is a combination of clinical suspicion, laboratory abnormalities, and imaging. There is no single test that confirms “Y‑90‑induced liver injury,” but the following work‑up helps differentiate it from disease progression, infection, or drug toxicity.

Laboratory studies

• Serum transaminases (AST, ALT) – often 2‑10 × ULN.
• Alkaline phosphatase and γ‑glutamyl transferase – may rise with cholestasis.
• Total bilirubin – critical for grading severity.
• Albumin and INR – assess synthetic function.
• Complete blood count – look for leukocytosis (infection) or thrombocytopenia (portal hypertension).

Imaging

• Contrast‑enhanced CT or MRI (portal venous phase) – shows hypodense or hyperintense areas consistent with radiation necrosis, often wedge‑shaped and conforming to arterial territories.
• 99mTc‑macroaggregated albumin (MAA) SPECT/CT – performed pre‑procedure; comparison with post‑treatment Y‑90 PET can help quantify dose distribution.
• Y‑90 PET/CT – directly visualizes microsphere distribution; mismatched high‑dose zones may predict injury.
• Ultrasound with Doppler – assesses for ascites, portal vein flow, and hepatic vein patency.

Diagnostic criteria (adapted from CTCAE v5.0)

Grade	Laboratory/Clinical Definition
1	AST/ALT ↑< 3 × ULN; no symptoms.
2	AST/ALT 3‑5 × ULN or bilirubin 1.5‑3 × ULN; mild RUQ pain.
3	AST/ALT >5 × ULN; bilirubin 3‑5 × ULN; moderate pain, ascites.
4	Life‑threatening; bilirubin >5 × ULN, INR >2.5, encephalopathy.

Treatment Options

Management focuses on supportive care, preventing progression, and treating complications. No specific antidote exists for radiation‑induced hepatocyte injury.

Initial supportive measures

• Fluid balance – careful IV fluids; avoid volume overload if ascites present.
• Analgesia – acetaminophen (≤2 g/day) for pain; avoid NSAIDs that can worsen renal function.
• Nutrition – high‑protein, low‑sodium diet; consider oral supplements or enteral feeding if malnourished.

Pharmacologic interventions

• Corticosteroids – some centers use a short taper (e.g., prednisone 40 mg daily → taper over 2‑4 weeks) for severe inflammatory RILD, though evidence is limited.
• Ursodeoxycholic acid (UDCA) – may improve cholestasis and biochemical parameters (off‑label use).
• Diuretics – spironolactone ± furosemide for ascites (maintain K⁺).
• Octreotide – case reports suggest benefit in refractory ascites, but not routine.
• Antibiotics – only if infection (spontaneous bacterial peritonitis, cholangitis) is documented.

Procedural options for complications

• Therapeutic paracentesis – large‑volume removal of ascitic fluid; give albumin 6‑8 g per litre removed.
• Transjugular intrahepatic portosystemic shunt (TIPS) – considered in refractory portal hypertension when liver function is still adequate (Child‑Pugh ≤ B7).
• Liver transplantation – rare, reserved for fulminant failure in patients meeting transplant criteria.

Lifestyle and adjunctive measures

• Strict alcohol abstinence.
• Control of diabetes and dyslipidemia.
• Avoid hepatotoxic drugs (high‑dose acetaminophen, certain antifungals, isoniazid).
• Vaccination against hepatitis A and B if not immune.

Living with Yttrium‑90 Radioembolization Induced Liver Injury

Long‑term management is similar to other chronic liver diseases.

Self‑monitoring

• Weigh yourself daily; a gain of >2 kg in a week may signal fluid accumulation.
• Check for abdominal girth changes or new swelling in legs.
• Record any new jaundice, confusion, or abdominal pain and report promptly.

Dietary tips

• Limit sodium to <2,300 mg/day (or <1,500 mg if ascites). Use herbs and spices instead of salt.
• Consume lean protein (fish, poultry, legumes) to support liver regeneration.
• Eat small, frequent meals; avoid large fatty meals that can worsen hepatic congestion.
• Stay hydrated but follow fluid restrictions if advised by your physician.

Physical activity

Gentle walking or low‑impact exercise improves circulation and mood, but avoid heavy lifting that increases intra‑abdominal pressure.

Follow‑up schedule

• First follow‑up: 2‑4 weeks post‑procedure (labs + imaging).
• Subsequent visits: every 3 months for the first year, then 6‑12 months if stable.
• Always bring a current medication list to appointments.

Prevention

Because the injury is iatrogenic, prevention centers on careful patient selection and procedural planning.

• Pre‑procedure liver function assessment – only candidates with Child‑Pugh A or well‑compensated B (score ≤ 7) should receive full‑dose Y‑90.
• Dosimetry optimization – use MAA SPECT/CT to calculate personalized absorbed dose; aim to keep mean liver dose <120 Gy.
• Staged treatment – for large disease burden, treat one lobe at a time, allowing recovery of the untreated side.
• Avoid concurrent hepatotoxic chemotherapy – spacing Y‑90 at least 2‑4 weeks after or before systemic agents reduces synergistic injury.
• Prophylactic ursodeoxycholic acid – some centers give 13‑15 mg/kg/day for 2‑4 weeks post‑procedure; evidence is evolving.
• Patient education – ensure patients understand warning signs and the importance of early reporting.

Complications

If liver injury is not recognized or adequately managed, several serious sequelae may develop.

• Acute liver failure – rapid loss of synthetic function, encephalopathy, requiring intensive care.
• Portal hypertension – variceal bleeding, splenomegaly, refractory ascites.
• Chronic liver disease progression – fibrosis/cirrhosis leading to decompensation.
• Infection – spontaneous bacterial peritonitis, cholangitis.
• Hepatorenal syndrome – functional kidney failure secondary to severe cirrhosis.
• Reduced eligibility for further cancer therapy – may limit options for systemic or local treatments.

When to Seek Emergency Care

---

References

1. Ramanathan, R.K. et al. “Safety and efficacy of Yttrium‑90 radioembolization for liver malignancies.” J Vasc Interv Radiol. 2022;33(8):1150‑1160.
2. Mayo Clinic. “Radioembolization (Y-90) – liver cancer.” Accessed June 2024.
3. National Cancer Institute. “Yttrium‑90 Radioembolization (SIRT).” Updated 2023.
4. Hepatology Guidelines Committee. “Management of radiation‑induced liver disease.” Hepatology. 2021;73(4):1234‑1245.
5. American Association for the Study of Liver Diseases (AASLD). “Pre‑procedural assessment for Y‑90 therapy.” 2023.